VISICORT partners NUI Galway, Orbsen, and Pintail are involved in NEPHSTROM, a new European project, which was launched last week. NEPHSTROM involves eleven partners from Ireland, the UK, Germany, and the Netherlands, and has received €6 million funding under the European Union’s Horizon 2020 funding programme. NEPHSTROM will evaluate the clinical safety and efficacy of a next-generation cell therapy discovered by Galway-based Orbsen Therapeutics, to combat diabetic kidney disease. Find out more about the project at www.nephstrom.eu.
Our sister project REDDSTAR and Leiden University Medical Center are co-organizing EU MSC2 2015, a meeting in Leiden, NL on September 7th and 8th to bring together nine EU-funded, mesenchymal stromal cell-focussed consortia. Projects include: REDDSTAR, REACH, RETHRIM, Stellar, MERLIN, Nephstrom, SCIENCE, VISICORT and Adipoa-2. This two day, interactive meeting will be held at the Stadsgehoorzaal Leiden.
The objectives of the meeting are to:
- Enhance knowledge-sharing between EU research groups working in the mesenchymal stromal cell biology domain
- Engage with European Commission Project Officers and other stakeholders from International Society of Cellular Therapy, stem cell ethicists and the European Medicines Agency (EMA)
- Assemble trans-disciplinary research groups working across the global health spectrum but with a common focus of mesenchymal stromal cell biology
- Bring up-and-coming researchers together for networking purposes, and to explore future consortium building and international funding application opportunities
Expected impacts and outcomes:
- Provide opportunities to develop new mesenchymal stromal cell networks
- Disseminate the findings and challenges between MSC-focussed consortia
- Improve the communication potential of research, outcomes and the value of the research
- Explore potential for new commercial technologies
- Collectively enhance the quality and impact of planned clinical trials
These EU projects are:
- Boosting human capital: 20-30 positions created
- Improving the quality of life for European citizens
- Progressing the clinical translation of MSC research and developments
For queries: LeidenRM@gmail.com
Danielle Nicholson, Orbsen Therapeutics, NUI Galway and Brigitte Wieles, Project Manager LUMC
The VISICORT project marked the end of the first year of its work with a plenary meeting at the Charité Campus Virchow Klinikum in Berlin on Friday, May 29. Following an overview of the management of the project, scientists involved in the project’s preclinical workpackages reported on the research carried out in the six months since the last plenary. The meeting also heard updates on recruitment for VISICORT’s clinical trial, and the development of the sample tracking system that will allow researchers to manage the movement of thousands of samples between clinical sites, storage facilities, and research laboratories. An afternoon breakout session, held in Charité’s Eye Clinic Laboratory, provided training in sampling protocols for the clinical researchers involved in the project. The meeting concluded with a discussion on dissemination and exploitation of the project’s results.
The winners of the schools science video competition, ReelLIFE SCIENCE were announced this week as part of Science Week 2014. The primary school category winners are Sooey National School, Co. Sligo, with Julien Torrades from Summerhill College, Sligo taking first place at secondary school level.
One video in the “Vision” category (which was sponsored by VISICORT) entitled “How We See the World”, made it to the final shortlist. The budding filmmakers from St. Andrew’s College in Blackrock, Co. Dublin will be treated to lunch and a tour of the Biostor facility in Wexford.
You can read all about the winners and view the videos here.
In der Oktoberausgabe des renomierten Augenspiegels wird über das im Rahmen des siebten Förderprogramms der Europäischen Gemeinschaft (FP7) bewilligte Forschungsprojekt VISICORT berichtet. Die immun-vermittelte Abstossung von allogenen (nicht-verwandten) Organen ist nach wie vor ein grosses Problem in der Transplantationsmedizin, welches auch durch die Verabreichung von immunsuppressiven Medikamenten nicht nachhaltig verhindert werden kann. Read more
New research from NUI Galway is using adult stem cells in the fight against cornea transplant rejection. The research has been published in the American Journal of Transplantation, and underpins a pan-European project which hopes to help the 100,000 people worldwide who undergo cornea transplant procedures each year.
VISICORT recently featured in the NUI Galway Magazine ‘Research Matters’ in an article titled ‘VISICORT – NUI Galway to Lead New 6 Million EU Project Tackling Corneal Transplanatation Failure.’
- VISICORT publication in the Official Journal of the Transplantation SocietySeptember 6, 2019 - 11:34 am
- VISICORT PI Ritter, NUI Galway joins Therapeutics Delivery COST ActionAugust 26, 2019 - 7:06 am
- VISICORT PIs present at Societas Ophthalmologica EuropæaJune 24, 2019 - 8:20 am
- International Clinical Trials Day 2019, GalwayJune 10, 2019 - 10:38 am
- Interview: Lisa Imrie, U of Edinburgh uses the VISICORT BiobankMay 31, 2019 - 7:58 am
- New VISICORT publication from NUI Galway teamMay 21, 2019 - 11:11 am
- Prof Ritter presents at ARVO 2019, CanadaMay 13, 2019 - 9:06 am
- PI Conor Murphy presents VISICORT at Royal Victoria Eye and Ear HospitalMay 1, 2019 - 1:25 pm
- VISICORT presentation in Berlin aims to recruit potential patients to the clinical trialApril 29, 2019 - 8:22 am
- VISICORT PI Nico Degauque, INSERM presents at Swedish Registry for Corneal TransplantApril 26, 2019 - 9:52 am
- Two VISICORT PIs involved in new COST ActionApril 11, 2019 - 2:47 pm
- Partners at CCMI offer training workshopsMarch 26, 2019 - 12:27 pm
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602470. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.